NovoCure Ltd [NVCR] stock is trading at $17.75, down -2.47%. An important factor to consider is whether the stock is rising or falling in short-term value. The NVCR shares have gain 3.80% over the last week, with a monthly amount glided 7.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on December 02, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $30 from $18. Previously, H.C. Wainwright upgraded its rating to Buy on October 16, 2024, and elevated its price target to $30. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on August 08, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 04, 2023, and assigned it a price target of $51. In a note dated July 31, 2023, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $33.
NovoCure Ltd [NVCR] stock has fluctuated between $14.17 and $34.13 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $17.75 at the most recent close of the market. An investor can expect a potential return of 69.01% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 621.71M for the trailing twelve months, which represents a growth of 11.91%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.45 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 1.47. On the other hand, the Quick Ratio is 1.41, and the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 3.18, the price to book ratio is 5.47.
Transactions by insiders
Recent insider trading involved Paravasthu Mukund, Chief Operating Officer, that happened on May 03 ’25 when 592.0 shares were sold. Officer, MUKUND PARAVASTHU completed a deal on May 05 ’25 to buy 592.0 shares. Meanwhile, Chief Innovation Officer Weinberg Uri sold 268.0 shares on Mar 03 ’25.
